Phase I Human Analytics (HALO) Study

This study is evaluating a new procedure for treating prostate cancer using MRI-guided focused treatment. It uses detailed imaging to precisely target and destroy cancer within the prostate while sparing surrounding tissue, aiming to reduce side effects compared to full prostate removal or whole-gland radiation. **You may be eligible if:** - You are a male aged 45 or older - You have been diagnosed with prostate cancer (adenocarcinoma) - Your cancer is low to intermediate risk (Gleason score 7 or lower, confined to the prostate) - You have 3 or fewer cancer-positive biopsy cores - Your cancer is visible and confirmed on MRI - You are in generally good health and can tolerate anesthesia - You have not had a prostate biopsy in the past 6 weeks **You may NOT be eligible if:** - You have a metal implant or condition that prevents MRI - You have severe urinary symptoms (high prostate symptom score) - You had another cancer in the past 3 years - You have diabetes or are a smoker Talk to your doctor to see if this trial is right for you.